Loading
RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.94, animal model 0.42, genetic association 0.28, somatic mutation 0.91). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma.
In plain words · RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling.
No product in this corpus aims at RASA1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA RASA1: RNA tissue enhanced (placenta 91 nTPM); high antibody staining in 3 normal tissues. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer (all types), Skin cancer (all types), Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P20936; CIViC gene RASA1; IntOGen RASA1; Human Protein Atlas RASA1 tissue; Open Targets ENSG00000145715 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Trahey et al, Science, 1988, "Molecular cloning of two types of GAP complementary DNA from human placenta". Source.
Sources: HGNC HGNC:9871 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P20936 (protein name, function text, keywords and locations (REST API)); CIViC gene RASA1 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000145715 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.53, gastric cancer 0.51, skin cancer 0.52, basal cell carcinoma 0.52, lung cancer 0.53 (GraphQL API, CC0)); IntOGen RASA1 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling. Location: Cytoplasm (UniProt). Locus 5q14.3 (HGNC).
RNA: tissue enhanced (placenta 91 nTPM), detected in all normal tissues.
No cancer stained high; medium in cervical cancer, endometrial cancer, lung cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RASA1" OR ABSTRACT:"RASA1" OR TITLE:"RAS p21 protein activator 1" OR ABSTRACT:"RAS p21 protein activator 1" OR TITLE:"Ras GTPase-activating protein 1" OR ABSTRACT:"Ras GTPase-activating protein 1" OR TITLE:"CM-AVM" OR ABSTRACT:"CM-AVM" OR TITLE:"p120GAP" OR ABSTRACT:"p120GAP" OR TITLE:"p120RASGAP" OR ABSTRACT:"p120RASGAP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RASA1, not a curated reading list.
Shares Basal cell carcinoma, Skin cancer (all types), CIViC, Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), CIViC, IntOGen.
Shares Basal cell carcinoma, Skin cancer (all types), Open Targets Platform, Colorectal cancer.
Shares Basal cell carcinoma, IntOGen, Lung cancer (all types), Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), Open Targets Platform.